Abstract
There is an urgent need to develop new drugs for the treatment of tuberculosis, particularly against latent/persistent forms of the causative agent, Mycobacterium tuberculosis. In this issue of Chemistry & Biology, Krieger and colleagues use a structure-guided approach to develop novel inhibitors of malate synthase, a target in the glyoxylate shunt that is critical for pathogen survival in chronic infection.